BOS Asset Management LLC Reduces Stock Holdings in Eli Lilly and Company (NYSE:LLY)

BOS Asset Management LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,785 shares of the company’s stock after selling 46 shares during the quarter. Eli Lilly and Company accounts for 2.2% of BOS Asset Management LLC’s portfolio, making the stock its 10th largest holding. BOS Asset Management LLC’s holdings in Eli Lilly and Company were worth $6,011,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Capital Planning LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $6,916,000. M&G Plc acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $8,896,000. BTC Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $1,432,000. Finally, High Net Worth Advisory Group LLC grew its holdings in shares of Eli Lilly and Company by 1.4% during the first quarter. High Net Worth Advisory Group LLC now owns 4,919 shares of the company’s stock valued at $3,827,000 after buying an additional 67 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Berenberg Bank raised their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $979.29.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $916.33 on Thursday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53. The company’s fifty day moving average price is $919.25 and its 200 day moving average price is $855.84. The company has a market capitalization of $870.88 billion, a PE ratio of 134.95, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.